nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyproterone acetate—CYP19A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0152	0.0701	CbGpPWpGaD
Cyproterone acetate—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.0149	0.0684	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.0121	0.0557	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptors—NR1I2—bone cancer	0.00875	0.0403	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.00835	0.0384	CbGpPWpGaD
Cyproterone acetate—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.00703	0.0323	CbGpPWpGaD
Cyproterone acetate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.00693	0.0319	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00692	0.0318	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.00664	0.0305	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00656	0.0302	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00634	0.0292	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00525	0.0241	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Tryptophan metabolism—CYP3A4—bone cancer	0.00378	0.0174	CbGpPWpGaD
Cyproterone acetate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.0037	0.017	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.00353	0.0162	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Ovarian Infertility Genes—CDK4—bone cancer	0.00313	0.0144	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00305	0.014	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00301	0.0139	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.00268	0.0123	CbGpPWpGaD
Cyproterone acetate—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.00267	0.0123	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00247	0.0114	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.00233	0.0107	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00199	0.00917	CbGpPWpGaD
Cyproterone acetate—Ill-defined disorder—Cisplatin—bone cancer	0.00191	0.00244	CcSEcCtD
Cyproterone acetate—Anaemia—Cisplatin—bone cancer	0.0019	0.00243	CcSEcCtD
Cyproterone acetate—Phlebitis—Doxorubicin—bone cancer	0.00189	0.00241	CcSEcCtD
Cyproterone acetate—Hot flush—Epirubicin—bone cancer	0.00188	0.0024	CcSEcCtD
Cyproterone acetate—Thrombophlebitis—Doxorubicin—bone cancer	0.00188	0.0024	CcSEcCtD
Cyproterone acetate—Diabetes mellitus—Doxorubicin—bone cancer	0.00187	0.00239	CcSEcCtD
Cyproterone acetate—Dermatitis exfoliative—Epirubicin—bone cancer	0.00186	0.00238	CcSEcCtD
Cyproterone acetate—Menopausal symptoms—Epirubicin—bone cancer	0.00186	0.00238	CcSEcCtD
Cyproterone acetate—Malaise—Cisplatin—bone cancer	0.00186	0.00237	CcSEcCtD
Cyproterone acetate—Leukopenia—Cisplatin—bone cancer	0.00184	0.00235	CcSEcCtD
Cyproterone acetate—AR—FOXA1 transcription factor network—JUN—bone cancer	0.00182	0.00836	CbGpPWpGaD
Cyproterone acetate—Eczema—Doxorubicin—bone cancer	0.00181	0.00231	CcSEcCtD
Cyproterone acetate—Hepatic failure—Doxorubicin—bone cancer	0.00181	0.00231	CcSEcCtD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.0018	0.00828	CbGpPWpGaD
Cyproterone acetate—Cardiac failure—Epirubicin—bone cancer	0.0018	0.0023	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Epirubicin—bone cancer	0.00179	0.00229	CcSEcCtD
Cyproterone acetate—Mood swings—Methotrexate—bone cancer	0.00178	0.00227	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00174	0.00222	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00174	0.008	CbGpPWpGaD
Cyproterone acetate—Hot flush—Doxorubicin—bone cancer	0.00174	0.00222	CcSEcCtD
Cyproterone acetate—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.00174	0.00798	CbGpPWpGaD
Cyproterone acetate—Liver function test abnormal—Methotrexate—bone cancer	0.00173	0.00221	CcSEcCtD
Cyproterone acetate—Discomfort—Cisplatin—bone cancer	0.00173	0.00221	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.00173	0.00796	CbGpPWpGaD
Cyproterone acetate—Affect lability—Epirubicin—bone cancer	0.00173	0.00221	CcSEcCtD
Cyproterone acetate—Migraine—Epirubicin—bone cancer	0.00173	0.00221	CcSEcCtD
Cyproterone acetate—Menopausal symptoms—Doxorubicin—bone cancer	0.00172	0.0022	CcSEcCtD
Cyproterone acetate—Dermatitis exfoliative—Doxorubicin—bone cancer	0.00172	0.0022	CcSEcCtD
Cyproterone acetate—AR—Gene Expression—ZNF77—bone cancer	0.0017	0.00782	CbGpPWpGaD
Cyproterone acetate—Breast disorder—Methotrexate—bone cancer	0.0017	0.00217	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00169	0.00779	CbGpPWpGaD
Cyproterone acetate—Oedema—Cisplatin—bone cancer	0.00168	0.00215	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00167	0.00769	CbGpPWpGaD
Cyproterone acetate—Cardiac failure—Doxorubicin—bone cancer	0.00166	0.00213	CcSEcCtD
Cyproterone acetate—Mood swings—Epirubicin—bone cancer	0.00166	0.00213	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Doxorubicin—bone cancer	0.00166	0.00212	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Cisplatin—bone cancer	0.00165	0.00211	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Cisplatin—bone cancer	0.00165	0.0021	CcSEcCtD
Cyproterone acetate—Blood creatinine increased—Epirubicin—bone cancer	0.00164	0.0021	CcSEcCtD
Cyproterone acetate—Tachycardia—Cisplatin—bone cancer	0.00164	0.0021	CcSEcCtD
Cyproterone acetate—Skin disorder—Cisplatin—bone cancer	0.00163	0.00209	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Cisplatin—bone cancer	0.00162	0.00208	CcSEcCtD
Cyproterone acetate—Asthma—Methotrexate—bone cancer	0.00162	0.00207	CcSEcCtD
Cyproterone acetate—Liver function test abnormal—Epirubicin—bone cancer	0.00162	0.00207	CcSEcCtD
Cyproterone acetate—Anorexia—Cisplatin—bone cancer	0.0016	0.00205	CcSEcCtD
Cyproterone acetate—Affect lability—Doxorubicin—bone cancer	0.0016	0.00204	CcSEcCtD
Cyproterone acetate—Migraine—Doxorubicin—bone cancer	0.0016	0.00204	CcSEcCtD
Cyproterone acetate—Pancreatitis—Methotrexate—bone cancer	0.00159	0.00203	CcSEcCtD
Cyproterone acetate—Breast disorder—Epirubicin—bone cancer	0.00159	0.00203	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00158	0.00202	CcSEcCtD
Cyproterone acetate—Hypotension—Cisplatin—bone cancer	0.00157	0.00201	CcSEcCtD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.00157	0.0072	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	0.00156	0.00718	CbGpPWpGaD
Cyproterone acetate—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00155	0.00198	CcSEcCtD
Cyproterone acetate—Muscular weakness—Epirubicin—bone cancer	0.00155	0.00198	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00154	0.0071	CbGpPWpGaD
Cyproterone acetate—Mood swings—Doxorubicin—bone cancer	0.00154	0.00197	CcSEcCtD
Cyproterone acetate—Blood creatinine increased—Doxorubicin—bone cancer	0.00152	0.00194	CcSEcCtD
Cyproterone acetate—Asthma—Epirubicin—bone cancer	0.00152	0.00194	CcSEcCtD
Cyproterone acetate—Liver function test abnormal—Doxorubicin—bone cancer	0.0015	0.00192	CcSEcCtD
Cyproterone acetate—Dyspnoea—Cisplatin—bone cancer	0.0015	0.00191	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.0015	0.00688	CbGpPWpGaD
Cyproterone acetate—Erectile dysfunction—Methotrexate—bone cancer	0.00149	0.00191	CcSEcCtD
Cyproterone acetate—Pancreatitis—Epirubicin—bone cancer	0.00149	0.0019	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Methotrexate—bone cancer	0.00148	0.00189	CcSEcCtD
Cyproterone acetate—Breast disorder—Doxorubicin—bone cancer	0.00147	0.00188	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00146	0.00187	CcSEcCtD
Cyproterone acetate—Decreased appetite—Cisplatin—bone cancer	0.00146	0.00187	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.00146	0.00671	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal disorder—Cisplatin—bone cancer	0.00145	0.00185	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00145	0.00667	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00144	0.00662	CbGpPWpGaD
Cyproterone acetate—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00143	0.00183	CcSEcCtD
Cyproterone acetate—Muscular weakness—Doxorubicin—bone cancer	0.00143	0.00183	CcSEcCtD
Cyproterone acetate—Renal failure—Methotrexate—bone cancer	0.00142	0.00182	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.00142	0.00652	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.0014	0.00646	CbGpPWpGaD
Cyproterone acetate—Asthma—Doxorubicin—bone cancer	0.0014	0.00179	CcSEcCtD
Cyproterone acetate—Pollakiuria—Epirubicin—bone cancer	0.0014	0.00179	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.0014	0.00642	CbGpPWpGaD
Cyproterone acetate—Sweating—Methotrexate—bone cancer	0.00139	0.00177	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00139	0.00638	CbGpPWpGaD
Cyproterone acetate—Photosensitivity reaction—Epirubicin—bone cancer	0.00139	0.00177	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Cisplatin—bone cancer	0.00138	0.00177	CcSEcCtD
Cyproterone acetate—Weight increased—Epirubicin—bone cancer	0.00138	0.00176	CcSEcCtD
Cyproterone acetate—Haematuria—Methotrexate—bone cancer	0.00138	0.00176	CcSEcCtD
Cyproterone acetate—Pancreatitis—Doxorubicin—bone cancer	0.00138	0.00176	CcSEcCtD
Cyproterone acetate—Weight decreased—Epirubicin—bone cancer	0.00137	0.00175	CcSEcCtD
Cyproterone acetate—Hyperglycaemia—Epirubicin—bone cancer	0.00137	0.00175	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Methotrexate—bone cancer	0.00137	0.00175	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.00137	0.00628	CbGpPWpGaD
Cyproterone acetate—Renal failure—Epirubicin—bone cancer	0.00133	0.0017	CcSEcCtD
Cyproterone acetate—Body temperature increased—Cisplatin—bone cancer	0.00133	0.0017	CcSEcCtD
Cyproterone acetate—Jaundice—Epirubicin—bone cancer	0.00132	0.00169	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.00131	0.00605	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.00131	0.00604	CbGpPWpGaD
Cyproterone acetate—Haemoglobin—Methotrexate—bone cancer	0.0013	0.00167	CcSEcCtD
Cyproterone acetate—Hepatitis—Methotrexate—bone cancer	0.0013	0.00166	CcSEcCtD
Cyproterone acetate—Haemorrhage—Methotrexate—bone cancer	0.0013	0.00166	CcSEcCtD
Cyproterone acetate—Sweating—Epirubicin—bone cancer	0.0013	0.00166	CcSEcCtD
Cyproterone acetate—Pollakiuria—Doxorubicin—bone cancer	0.0013	0.00166	CcSEcCtD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.0013	0.00596	CbGpPWpGaD
Cyproterone acetate—Haematuria—Epirubicin—bone cancer	0.00129	0.00165	CcSEcCtD
Cyproterone acetate—NR3C1—Gene Expression—ZNF77—bone cancer	0.00129	0.00593	CbGpPWpGaD
Cyproterone acetate—Photosensitivity reaction—Doxorubicin—bone cancer	0.00128	0.00164	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Epirubicin—bone cancer	0.00128	0.00164	CcSEcCtD
Cyproterone acetate—Weight increased—Doxorubicin—bone cancer	0.00128	0.00163	CcSEcCtD
Cyproterone acetate—Weight decreased—Doxorubicin—bone cancer	0.00127	0.00162	CcSEcCtD
Cyproterone acetate—Hyperglycaemia—Doxorubicin—bone cancer	0.00127	0.00162	CcSEcCtD
Cyproterone acetate—Visual impairment—Methotrexate—bone cancer	0.00125	0.0016	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00125	0.00574	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Cisplatin—bone cancer	0.00124	0.00158	CcSEcCtD
Cyproterone acetate—Renal failure—Doxorubicin—bone cancer	0.00123	0.00157	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Methotrexate—bone cancer	0.00123	0.00157	CcSEcCtD
Cyproterone acetate—Haemoglobin—Epirubicin—bone cancer	0.00122	0.00156	CcSEcCtD
Cyproterone acetate—Jaundice—Doxorubicin—bone cancer	0.00122	0.00156	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.00122	0.00561	CbGpPWpGaD
Cyproterone acetate—Haemorrhage—Epirubicin—bone cancer	0.00121	0.00155	CcSEcCtD
Cyproterone acetate—Hepatitis—Epirubicin—bone cancer	0.00121	0.00155	CcSEcCtD
Cyproterone acetate—Eye disorder—Methotrexate—bone cancer	0.00121	0.00155	CcSEcCtD
Cyproterone acetate—Asthenia—Cisplatin—bone cancer	0.00121	0.00154	CcSEcCtD
Cyproterone acetate—Sweating—Doxorubicin—bone cancer	0.0012	0.00153	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—NR1I2—bone cancer	0.00119	0.0055	CbGpPWpGaD
Cyproterone acetate—Haematuria—Doxorubicin—bone cancer	0.00119	0.00153	CcSEcCtD
Cyproterone acetate—Connective tissue disorder—Epirubicin—bone cancer	0.00119	0.00153	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—MDM2—bone cancer	0.00119	0.00547	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	0.00119	0.00546	CbGpPWpGaD
Cyproterone acetate—Hepatobiliary disease—Doxorubicin—bone cancer	0.00118	0.00151	CcSEcCtD
Cyproterone acetate—Angiopathy—Methotrexate—bone cancer	0.00118	0.0015	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00117	0.0054	CbGpPWpGaD
Cyproterone acetate—Immune system disorder—Methotrexate—bone cancer	0.00117	0.0015	CcSEcCtD
Cyproterone acetate—Visual impairment—Epirubicin—bone cancer	0.00117	0.0015	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Methotrexate—bone cancer	0.00117	0.00149	CcSEcCtD
Cyproterone acetate—Chills—Methotrexate—bone cancer	0.00116	0.00149	CcSEcCtD
Cyproterone acetate—Diarrhoea—Cisplatin—bone cancer	0.00115	0.00147	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Epirubicin—bone cancer	0.00115	0.00147	CcSEcCtD
Cyproterone acetate—Alopecia—Methotrexate—bone cancer	0.00115	0.00147	CcSEcCtD
Cyproterone acetate—Mental disorder—Methotrexate—bone cancer	0.00114	0.00145	CcSEcCtD
Cyproterone acetate—Eye disorder—Epirubicin—bone cancer	0.00114	0.00145	CcSEcCtD
Cyproterone acetate—Malnutrition—Methotrexate—bone cancer	0.00113	0.00144	CcSEcCtD
Cyproterone acetate—Haemoglobin—Doxorubicin—bone cancer	0.00113	0.00144	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.00113	0.00518	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.00112	0.00517	CbGpPWpGaD
Cyproterone acetate—Hepatitis—Doxorubicin—bone cancer	0.00112	0.00144	CcSEcCtD
Cyproterone acetate—Haemorrhage—Doxorubicin—bone cancer	0.00112	0.00144	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.00111	0.00513	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.00111	0.0051	CbGpPWpGaD
Cyproterone acetate—Connective tissue disorder—Doxorubicin—bone cancer	0.0011	0.00141	CcSEcCtD
Cyproterone acetate—Angiopathy—Epirubicin—bone cancer	0.0011	0.00141	CcSEcCtD
Cyproterone acetate—Immune system disorder—Epirubicin—bone cancer	0.0011	0.0014	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.0011	0.00504	CbGpPWpGaD
Cyproterone acetate—Mediastinal disorder—Epirubicin—bone cancer	0.00109	0.0014	CcSEcCtD
Cyproterone acetate—Chills—Epirubicin—bone cancer	0.00109	0.00139	CcSEcCtD
Cyproterone acetate—Visual impairment—Doxorubicin—bone cancer	0.00108	0.00138	CcSEcCtD
Cyproterone acetate—Alopecia—Epirubicin—bone cancer	0.00107	0.00137	CcSEcCtD
Cyproterone acetate—Vomiting—Cisplatin—bone cancer	0.00107	0.00137	CcSEcCtD
Cyproterone acetate—Mental disorder—Epirubicin—bone cancer	0.00106	0.00136	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Doxorubicin—bone cancer	0.00106	0.00136	CcSEcCtD
Cyproterone acetate—Rash—Cisplatin—bone cancer	0.00106	0.00135	CcSEcCtD
Cyproterone acetate—Dermatitis—Cisplatin—bone cancer	0.00106	0.00135	CcSEcCtD
Cyproterone acetate—Malnutrition—Epirubicin—bone cancer	0.00106	0.00135	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00105	0.00484	CbGpPWpGaD
Cyproterone acetate—Eye disorder—Doxorubicin—bone cancer	0.00105	0.00134	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Methotrexate—bone cancer	0.00105	0.00134	CcSEcCtD
Cyproterone acetate—Anaemia—Methotrexate—bone cancer	0.00104	0.00133	CcSEcCtD
Cyproterone acetate—Tension—Epirubicin—bone cancer	0.00104	0.00133	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—JUN—bone cancer	0.00103	0.00476	CbGpPWpGaD
Cyproterone acetate—Angiopathy—Doxorubicin—bone cancer	0.00102	0.0013	CcSEcCtD
Cyproterone acetate—Malaise—Methotrexate—bone cancer	0.00102	0.0013	CcSEcCtD
Cyproterone acetate—Immune system disorder—Doxorubicin—bone cancer	0.00102	0.0013	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Doxorubicin—bone cancer	0.00101	0.00129	CcSEcCtD
Cyproterone acetate—Leukopenia—Methotrexate—bone cancer	0.00101	0.00129	CcSEcCtD
Cyproterone acetate—Chills—Doxorubicin—bone cancer	0.00101	0.00129	CcSEcCtD
Cyproterone acetate—Nausea—Cisplatin—bone cancer	0.000998	0.00128	CcSEcCtD
Cyproterone acetate—Alopecia—Doxorubicin—bone cancer	0.000993	0.00127	CcSEcCtD
Cyproterone acetate—Cough—Methotrexate—bone cancer	0.000986	0.00126	CcSEcCtD
Cyproterone acetate—Mental disorder—Doxorubicin—bone cancer	0.000985	0.00126	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Epirubicin—bone cancer	0.000981	0.00125	CcSEcCtD
Cyproterone acetate—Malnutrition—Doxorubicin—bone cancer	0.000978	0.00125	CcSEcCtD
Cyproterone acetate—Anaemia—Epirubicin—bone cancer	0.000977	0.00125	CcSEcCtD
Cyproterone acetate—Agitation—Epirubicin—bone cancer	0.000972	0.00124	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.000964	0.00443	CbGpPWpGaD
Cyproterone acetate—Tension—Doxorubicin—bone cancer	0.00096	0.00123	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000955	0.00122	CcSEcCtD
Cyproterone acetate—Malaise—Epirubicin—bone cancer	0.000954	0.00122	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—JUN—bone cancer	0.000951	0.00437	CbGpPWpGaD
Cyproterone acetate—Discomfort—Methotrexate—bone cancer	0.00095	0.00121	CcSEcCtD
Cyproterone acetate—Syncope—Epirubicin—bone cancer	0.000948	0.00121	CcSEcCtD
Cyproterone acetate—Leukopenia—Epirubicin—bone cancer	0.000946	0.00121	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00093	0.00428	CbGpPWpGaD
Cyproterone acetate—Loss of consciousness—Epirubicin—bone cancer	0.000929	0.00119	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	0.000925	0.00425	CbGpPWpGaD
Cyproterone acetate—Cough—Epirubicin—bone cancer	0.000923	0.00118	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000914	0.0042	CbGpPWpGaD
Cyproterone acetate—Ill-defined disorder—Doxorubicin—bone cancer	0.000908	0.00116	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	0.000906	0.00417	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000904	0.00416	CbGpPWpGaD
Cyproterone acetate—Nervous system disorder—Methotrexate—bone cancer	0.000904	0.00116	CcSEcCtD
Cyproterone acetate—Anaemia—Doxorubicin—bone cancer	0.000904	0.00116	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Methotrexate—bone cancer	0.000903	0.00115	CcSEcCtD
Cyproterone acetate—Agitation—Doxorubicin—bone cancer	0.000899	0.00115	CcSEcCtD
Cyproterone acetate—Skin disorder—Methotrexate—bone cancer	0.000896	0.00114	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000894	0.00114	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Methotrexate—bone cancer	0.000891	0.00114	CcSEcCtD
Cyproterone acetate—Discomfort—Epirubicin—bone cancer	0.000889	0.00114	CcSEcCtD
Cyproterone acetate—Malaise—Doxorubicin—bone cancer	0.000882	0.00113	CcSEcCtD
Cyproterone acetate—Anorexia—Methotrexate—bone cancer	0.000879	0.00112	CcSEcCtD
Cyproterone acetate—Syncope—Doxorubicin—bone cancer	0.000877	0.00112	CcSEcCtD
Cyproterone acetate—Leukopenia—Doxorubicin—bone cancer	0.000876	0.00112	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000871	0.00401	CbGpPWpGaD
Cyproterone acetate—Oedema—Epirubicin—bone cancer	0.000863	0.0011	CcSEcCtD
Cyproterone acetate—Hypotension—Methotrexate—bone cancer	0.000862	0.0011	CcSEcCtD
Cyproterone acetate—Loss of consciousness—Doxorubicin—bone cancer	0.00086	0.0011	CcSEcCtD
Cyproterone acetate—Cough—Doxorubicin—bone cancer	0.000854	0.00109	CcSEcCtD
Cyproterone acetate—Shock—Epirubicin—bone cancer	0.000849	0.00108	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Epirubicin—bone cancer	0.000846	0.00108	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000846	0.00389	CbGpPWpGaD
Cyproterone acetate—Thrombocytopenia—Epirubicin—bone cancer	0.000845	0.00108	CcSEcCtD
Cyproterone acetate—Tachycardia—Epirubicin—bone cancer	0.000842	0.00108	CcSEcCtD
Cyproterone acetate—Skin disorder—Epirubicin—bone cancer	0.000838	0.00107	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	0.000838	0.00385	CbGpPWpGaD
Cyproterone acetate—Hyperhidrosis—Epirubicin—bone cancer	0.000834	0.00107	CcSEcCtD
Cyproterone acetate—AR—Gene Expression—FUS—bone cancer	0.00083	0.00382	CbGpPWpGaD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000827	0.00106	CcSEcCtD
Cyproterone acetate—Discomfort—Doxorubicin—bone cancer	0.000823	0.00105	CcSEcCtD
Cyproterone acetate—Anorexia—Epirubicin—bone cancer	0.000823	0.00105	CcSEcCtD
Cyproterone acetate—Dyspnoea—Methotrexate—bone cancer	0.000822	0.00105	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—EGFR—bone cancer	0.000813	0.00374	CbGpPWpGaD
Cyproterone acetate—Dyspepsia—Methotrexate—bone cancer	0.000812	0.00104	CcSEcCtD
Cyproterone acetate—Hypotension—Epirubicin—bone cancer	0.000806	0.00103	CcSEcCtD
Cyproterone acetate—Decreased appetite—Methotrexate—bone cancer	0.000802	0.00102	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.0008	0.00368	CbGpPWpGaD
Cyproterone acetate—Oedema—Doxorubicin—bone cancer	0.000798	0.00102	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000796	0.00102	CcSEcCtD
Cyproterone acetate—Fatigue—Methotrexate—bone cancer	0.000795	0.00102	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—NDUFA12—bone cancer	0.000788	0.00363	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000786	0.00362	CbGpPWpGaD
Cyproterone acetate—Shock—Doxorubicin—bone cancer	0.000786	0.001	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Doxorubicin—bone cancer	0.000783	0.001	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Doxorubicin—bone cancer	0.000782	0.000999	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—RB1—bone cancer	0.000782	0.0036	CbGpPWpGaD
Cyproterone acetate—Tachycardia—Doxorubicin—bone cancer	0.000779	0.000996	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000779	0.00358	CbGpPWpGaD
Cyproterone acetate—Skin disorder—Doxorubicin—bone cancer	0.000776	0.000991	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Doxorubicin—bone cancer	0.000772	0.000986	CcSEcCtD
Cyproterone acetate—Dyspnoea—Epirubicin—bone cancer	0.000769	0.000983	CcSEcCtD
Cyproterone acetate—Anorexia—Doxorubicin—bone cancer	0.000761	0.000973	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Methotrexate—bone cancer	0.00076	0.000971	CcSEcCtD
Cyproterone acetate—Dyspepsia—Epirubicin—bone cancer	0.00076	0.000971	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Methotrexate—bone cancer	0.000754	0.000963	CcSEcCtD
Cyproterone acetate—Decreased appetite—Epirubicin—bone cancer	0.00075	0.000959	CcSEcCtD
Cyproterone acetate—Hypotension—Doxorubicin—bone cancer	0.000746	0.000953	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000745	0.000952	CcSEcCtD
Cyproterone acetate—Fatigue—Epirubicin—bone cancer	0.000744	0.000951	CcSEcCtD
Cyproterone acetate—Constipation—Epirubicin—bone cancer	0.000738	0.000943	CcSEcCtD
Cyproterone acetate—Urticaria—Methotrexate—bone cancer	0.000733	0.000936	CcSEcCtD
Cyproterone acetate—Body temperature increased—Methotrexate—bone cancer	0.000729	0.000931	CcSEcCtD
Cyproterone acetate—Abdominal pain—Methotrexate—bone cancer	0.000729	0.000931	CcSEcCtD
Cyproterone acetate—Dyspnoea—Doxorubicin—bone cancer	0.000712	0.00091	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Epirubicin—bone cancer	0.000711	0.000909	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Epirubicin—bone cancer	0.000706	0.000902	CcSEcCtD
Cyproterone acetate—Dyspepsia—Doxorubicin—bone cancer	0.000703	0.000898	CcSEcCtD
Cyproterone acetate—Decreased appetite—Doxorubicin—bone cancer	0.000694	0.000887	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000689	0.000881	CcSEcCtD
Cyproterone acetate—Fatigue—Doxorubicin—bone cancer	0.000688	0.00088	CcSEcCtD
Cyproterone acetate—Urticaria—Epirubicin—bone cancer	0.000686	0.000876	CcSEcCtD
Cyproterone acetate—Constipation—Doxorubicin—bone cancer	0.000683	0.000872	CcSEcCtD
Cyproterone acetate—Abdominal pain—Epirubicin—bone cancer	0.000682	0.000872	CcSEcCtD
Cyproterone acetate—Body temperature increased—Epirubicin—bone cancer	0.000682	0.000872	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Methotrexate—bone cancer	0.000679	0.000868	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000677	0.00312	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000671	0.00308	CbGpPWpGaD
Cyproterone acetate—Asthenia—Methotrexate—bone cancer	0.000662	0.000845	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—JUN—bone cancer	0.00066	0.00304	CbGpPWpGaD
Cyproterone acetate—Feeling abnormal—Doxorubicin—bone cancer	0.000658	0.000841	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000653	0.000834	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—NT5C3A—bone cancer	0.000653	0.003	CbGpPWpGaD
Cyproterone acetate—Pruritus—Methotrexate—bone cancer	0.000652	0.000834	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000646	0.00297	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Epirubicin—bone cancer	0.000636	0.000812	CcSEcCtD
Cyproterone acetate—Urticaria—Doxorubicin—bone cancer	0.000634	0.000811	CcSEcCtD
Cyproterone acetate—Abdominal pain—Doxorubicin—bone cancer	0.000631	0.000807	CcSEcCtD
Cyproterone acetate—Body temperature increased—Doxorubicin—bone cancer	0.000631	0.000807	CcSEcCtD
Cyproterone acetate—Diarrhoea—Methotrexate—bone cancer	0.000631	0.000806	CcSEcCtD
Cyproterone acetate—NR3C1—Gene Expression—FUS—bone cancer	0.000629	0.0029	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—TP53—bone cancer	0.000627	0.00289	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000622	0.00286	CbGpPWpGaD
Cyproterone acetate—Asthenia—Epirubicin—bone cancer	0.000619	0.000791	CcSEcCtD
Cyproterone acetate—Pruritus—Epirubicin—bone cancer	0.000611	0.00078	CcSEcCtD
Cyproterone acetate—Dizziness—Methotrexate—bone cancer	0.00061	0.000779	CcSEcCtD
Cyproterone acetate—Diarrhoea—Epirubicin—bone cancer	0.00059	0.000754	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Doxorubicin—bone cancer	0.000588	0.000752	CcSEcCtD
Cyproterone acetate—Vomiting—Methotrexate—bone cancer	0.000586	0.000749	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000583	0.00268	CbGpPWpGaD
Cyproterone acetate—Rash—Methotrexate—bone cancer	0.000581	0.000743	CcSEcCtD
Cyproterone acetate—Dermatitis—Methotrexate—bone cancer	0.000581	0.000742	CcSEcCtD
Cyproterone acetate—Headache—Methotrexate—bone cancer	0.000578	0.000738	CcSEcCtD
Cyproterone acetate—AR—Gene Expression—NR1I2—bone cancer	0.000575	0.00265	CbGpPWpGaD
Cyproterone acetate—Asthenia—Doxorubicin—bone cancer	0.000573	0.000732	CcSEcCtD
Cyproterone acetate—Dizziness—Epirubicin—bone cancer	0.000571	0.000729	CcSEcCtD
Cyproterone acetate—Pruritus—Doxorubicin—bone cancer	0.000565	0.000722	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000561	0.00258	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.000553	0.00254	CbGpPWpGaD
Cyproterone acetate—Vomiting—Epirubicin—bone cancer	0.000549	0.000701	CcSEcCtD
Cyproterone acetate—Nausea—Methotrexate—bone cancer	0.000548	0.0007	CcSEcCtD
Cyproterone acetate—Diarrhoea—Doxorubicin—bone cancer	0.000546	0.000698	CcSEcCtD
Cyproterone acetate—Rash—Epirubicin—bone cancer	0.000544	0.000695	CcSEcCtD
Cyproterone acetate—Dermatitis—Epirubicin—bone cancer	0.000544	0.000695	CcSEcCtD
Cyproterone acetate—Headache—Epirubicin—bone cancer	0.000541	0.000691	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000533	0.00245	CbGpPWpGaD
Cyproterone acetate—Dizziness—Doxorubicin—bone cancer	0.000528	0.000675	CcSEcCtD
Cyproterone acetate—Nausea—Epirubicin—bone cancer	0.000513	0.000655	CcSEcCtD
Cyproterone acetate—Vomiting—Doxorubicin—bone cancer	0.000508	0.000649	CcSEcCtD
Cyproterone acetate—Rash—Doxorubicin—bone cancer	0.000503	0.000643	CcSEcCtD
Cyproterone acetate—Dermatitis—Doxorubicin—bone cancer	0.000503	0.000643	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000501	0.0023	CbGpPWpGaD
Cyproterone acetate—Headache—Doxorubicin—bone cancer	0.0005	0.000639	CcSEcCtD
Cyproterone acetate—Nausea—Doxorubicin—bone cancer	0.000474	0.000606	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000458	0.00211	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000447	0.00206	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000441	0.00203	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—NR1I2—bone cancer	0.000436	0.00201	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—EIF2S1—bone cancer	0.000425	0.00195	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000385	0.00177	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.00037	0.0017	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—EZH2—bone cancer	0.000369	0.0017	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—EIF2S1—bone cancer	0.000322	0.00148	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ENO2—bone cancer	0.000286	0.00132	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—EZH2—bone cancer	0.00028	0.00129	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—DHFR—bone cancer	0.000265	0.00122	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GNA11—bone cancer	0.000248	0.00114	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CYP3A4—bone cancer	0.000225	0.00103	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000224	0.00103	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTP1—bone cancer	0.000192	0.000885	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTGS2—bone cancer	9.96e-05	0.000458	CbGpPWpGaD
